The FDA has approved faricimab, a drug with the potential to reduce the number of injections needed to treat diabetic macular edema and neovascular age-related macular degeneration.
A recent market research report estimated that between 2021 and 2026, the market for virtual reality in healthcare will grow by nearly 35% annually, swelling the market to more than $40 billion.